A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat
A phase 2 trial of Toripalimab, Bevacizumab in hepatocellular carcinoma, run by Coherus Oncology, Inc., active and no longer recruiting.
Overview
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT06679985 by Coherus Oncology, Inc., with 72 participants planned, started 2024-12-20 and due to reach its primary completion in 2027-09. Interventions recorded: Casdozokitug, Toripalimab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialJUPITER-06
Shares Shanghai Junshi Biosciences, Toripalimab.
- TrialJUPITER-02
Shares Shanghai Junshi Biosciences, Toripalimab.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialStudy of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Bevacizumab, Hepatocellular carcinoma.